Combination chemotherapy for primary small intestinal lymphoma in the Middle East

Eur J Cancer Clin Oncol. 1989 May;25(5):851-6. doi: 10.1016/0277-5379(89)90131-4.

Abstract

Twelve patients with primary small intestinal lymphoma were followed prospectively for 3 years. Endoscopic abnormalities were diagnostic of lymphoma in all cases where the duodenum was involved (83%). In three cases (25%) the disease extended to the stomach. One patient (8%) had diffuse small cell cleaved and 11 (92%) diffuse large cell lymphoma stages I (8%), II (25%), III (58%) and IV (8%). Nine of them were unresectable and primarily treated with combination chemotherapy; 67% achieved complete remission, 22% partial response and 11% no response. Only one patient relapsed and achieved a second remission. All complete remission patients are currently alive and free of disease at a median follow-up of 36 months. Overall survival for all patients is 58%, and disease-free survival is 50%. No instance of chemotherapy-related bleeding or perforation was seen. Tetracycline was necessary for the treatment of IPSID-associated diarrhea and malabsorption in spite of cytotoxic chemotherapy.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Intestinal Neoplasms / drug therapy*
  • Intestine, Small
  • Leucovorin / administration & dosage
  • Lymphoma / drug therapy*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Prednisone / administration & dosage
  • Prospective Studies
  • Saudi Arabia
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Leucovorin
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOP-B protocol
  • M-BACOD protocol